Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:59:44 PM EDT
150.10
-1.08 (-0.71%)
Products, Regulatory, Earnings Announcements

Jazz Pharmaceuticals Announces Results From Phase 3 Study Of Xywav In Adult Patients With Idiopathic Hypersomnia

Published: 10/08/2020 13:01 GMT
Jazz Pharmaceuticals PLC (JAZZ) - Jazz Pharmaceuticals Announces Positive Top-line Results From Phase 3 Study of Xywav™ (calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution in Adult Patients With Idiopathic Hypersomnia.
Jazz Pharmaceuticals Plc - Clinically Meaningful and Highly Statistically Significant Results for Primary and Both Key Secondary Endpoints.
Jazz Pharmaceuticals Plc - U.S. Food and Drug Administration Grants Fast Track Designation to Xywav for Idiopathic Hypersomnia.
Jazz Pharmaceuticals Plc - Those Who Were Administered Xywav Showed Clinically Meaningful Maintenance of Efficacy for Ess, Pgic and Ihss.
Revenue is expected to be $576.66 Million
Adjusted EPS is expected to be $4.08

Next Quarter Revenue Guidance is expected to be $604.78 Million
Next Quarter EPS Guidance is expected to be $4.25

More details on our Analysts Page.